Hycamtin

GIF decision: Marketing prohibition

What does this decision mean?

  • Zakaz wprowadzania — Selected batches are subject to a marketing prohibition — the product cannot be distributed to pharmacies.

The identified deviation concerns the content parameter of the active substance topotecan; administering the medicine with an increased amount of topotecan compared to the declared dose may negatively affect treatment tolerance. Hematological toxic effects are dose‑dependent. Potential effects: hematological toxicity, complications of oncology treatment.

Download the app and stay informed

Get instant notifications about recalled products and protect your family.

Hycamtin
Risk Level
High
Manufacturer
Sandoz Pharmaceuticals d.d., Verovškova ulica 57, 1000 Ljubljana, Slovenia
Batch Number
BCUN3
Notice Date
02.10.2023
View official statement
Source: GIF view the official alert

What to do if you have this product?

A recall means the product may be unsafe. Here is what to do if you have it at home.

  1. 1

    Do not eat or use the product

    Stop using or consuming it immediately and keep it out of reach of children.

  2. 2

    Check the batch number and expiry date

    Compare the batch/lot number and the best-before or expiry date with the details in the alert — sometimes only specific batches are affected.

  3. 3

    Return it to the shop

    You can take the product back to the shop where you bought it. For a safety recall a refund is due even without a receipt.

  4. 4

    Get help and report it

    If you feel unwell after using the product, contact a doctor. You can also report the case to the relevant authority — GIS, GIF or UOKiK.

General guidance for recalled products in Poland. Always follow the specific instructions in the official alert and from the manufacturer or retailer.

Important Information

What You Should Know

Recommendations

Do not use Hycamtin with batch numbers BCUN2 and BCUN3; if you have these packs, return them to the pharmacy and consult a doctor or pharmacist.

Actions Taken

The Chief Pharmaceutical Inspector prohibited placing Hycamtin batches BCUN2 and BCUN3 on the market throughout the country and granted the decision immediate enforceability; an explanatory procedure ...

Need Help?

If you feel unwell after consuming this product, contact your doctor or call the poison control center.

Related

Other Notices